GO:0034375 high-density lipoprotein particle remodeling: Mechanism, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0034375 high-density lipoprotein particle remodeling describes the acquisition, loss, or modification of proteins and lipids within HDL particles, including triglyceride hydrolysis by hepatic lipase and cholesteryl ester transfer protein (CETP)-mediated lipid exchange.
• HDL remodeling is a dynamic postprandial and postabsorptive process that alters HDL subfraction distribution and function, with direct implications for atherosclerotic cardiovascular disease.
• Key molecular players include CETP, hepatic lipase (LIPC), phospholipid transfer protein (PLTP), lecithin-cholesterol acyltransferase (LCAT), apolipoprotein A-I (APOA1), and serum amyloid A (SAA) proteins.
• Postprandial remodeling of HDL following high saturated fat or high carbohydrate meals changes HDL lipid composition and particle size, linking diet to HDL function.
• HDL remodeling affects the osmotic properties of plasma and has been studied in non-mammalian models such as goldfish under critical salinity, indicating conserved biophysical roles.
• Therapeutic modulation of HDL remodeling, including triglyceride lowering with pemafibrate, has been evaluated for cardiovascular risk reduction, though outcomes have been mixed.
Description
High-density lipoprotein (HDL) particles are not static carriers of cholesterol; they undergo continuous remodeling in the circulation, a process formally captured by the Gene Ontology term GO:0034375, high-density lipoprotein particle remodeling. This biological process encompasses the acquisition, loss, or modification of proteins and lipids within an HDL particle, including the hydrolysis of triglycerides by hepatic lipase with subsequent loss of free fatty acids, and the transfer of cholesteryl esters from LDL to triglyceride-rich lipoproteins by cholesteryl ester transfer protein (CETP), with simultaneous transfer of triglyceride to LDL. Understanding this term is essential because HDL remodeling directly influences HDL subfraction distribution, reverse cholesterol transport efficiency, and cardiovascular risk. Research over the past decade has expanded the scope of HDL remodeling beyond classical lipid exchange. Postprandial studies show that meals high in saturated fat or carbohydrate acutely remodel HDL, altering particle size and composition. Proteomic and surfaceome analyses have begun to decode the dynamic protein interactions on the HDL surface that mediate these changes. Moreover, HDL remodeling has been linked to non-cardiovascular contexts, including renal fibrosis, where HDL nanoparticles spontaneously target damaged tubules and remodel fibrotic niches, and to osmotic regulation in fish under salinity stress. These findings underscore that GO:0034375 is a broadly relevant process with implications for cardiovascular disease, metabolic disorders, and beyond. For researchers, GO:0034375 provides a precise ontological framework to annotate genes, interpret lipidomics and proteomics data, and design experiments that perturb specific steps of HDL remodeling. The sections below detail the definition, key genes, regulatory mechanisms, disease associations, and state-of-the-art methods, including CRISPR-based models, for studying this process.
high-density lipoprotein particle remodeling At A Glance
| GO ID | GO:0034375 |
|---|---|
| GO term | high-density lipoprotein particle remodeling |
| Ontology | biological_process |
| Synonym | HDL remodeling; HDL remodelling; high-density lipoprotein particle remodelling |
| Major function | Modification of HDL protein and lipid composition, including triglyceride hydrolysis and CETP-mediated lipid exchange |
| Key enzymes | Hepatic lipase (LIPC), cholesteryl ester transfer protein (CETP), phospholipid transfer protein (PLTP), lecithin-cholesterol acyltransferase (LCAT) |
| Key apolipoproteins | APOA1, APOA2, APOC3, APOE, serum amyloid A (SAA) |
| Subcellular context | Extracellular space; circulating plasma lipoproteins |
| Related diseases | Atherosclerotic cardiovascular disease, dyslipidemia, renal fibrosis |
What Is GO:0034375?
GO:0034375, high-density lipoprotein particle remodeling, is defined as the acquisition, loss, or modification of a protein or lipid within a high-density lipoprotein particle. This includes the hydrolysis of triglyceride by hepatic lipase, with the subsequent loss of free fatty acid, and the transfer of cholesteryl esters from LDL to a triglyceride-rich lipoprotein particle by cholesteryl ester transfer protein (CETP), with the simultaneous transfer of triglyceride to LDL. In essence, it covers any biochemical event that changes the composition, size, or surface properties of an HDL particle after its initial assembly.
Why Is high-density lipoprotein particle remodeling Important in Cell Biology?
GO:0034375 is critically important because HDL remodeling determines the functional heterogeneity of HDL particles and their ability to mediate reverse cholesterol transport, antioxidant, and anti-inflammatory activities. Dysregulated HDL remodeling is associated with atherosclerotic cardiovascular disease, and therapeutic strategies that modulate HDL composition or subfraction distribution are actively being investigated. Beyond cardiovascular biology, HDL remodeling influences systemic processes such as renal fibrosis and osmotic balance in extreme environments, making it a nexus for interdisciplinary research.
• HDL remodeling controls the conversion of large, lipid-rich HDL2 to smaller, denser HDL3, affecting cholesterol efflux capacity.
• CETP-mediated exchange of cholesteryl esters and triglycerides is a central step in HDL remodeling and a drug target for cardiovascular disease.
• Postprandial remodeling after high-fat or high-carbohydrate meals alters HDL particle size and composition, linking diet to HDL function.
• HDL surfaceome interactions are dynamic and can be decoded to understand how remodeling affects receptor binding and signaling.
• Serum amyloid A (SAA) proteins can displace APOA1 on HDL during inflammation, remodeling the particle and altering its function.
• HDL remodeling affects plasma osmotic properties, as shown in goldfish under critical salinity, indicating conserved biophysical roles.
• HDL nanoparticles that target damaged renal tubules and remodel fibrotic niches highlight therapeutic potential beyond cardiovascular disease.
• Triglyceride-lowering therapies such as pemafibrate aim to modify HDL remodeling and reduce cardiovascular risk, though clinical outcomes require careful evaluation.
• Understanding HDL remodeling is essential for interpreting lipidomics and proteomics data in metabolic and cardiovascular research.
• CRISPR-based models of genes involved in HDL remodeling enable causal testing of specific steps in the process.
What Happens During high-density lipoprotein particle remodeling?
Triglyceride Hydrolysis by Hepatic Lipase
In simple terms: Hepatic lipase acts like a molecular scissors that cuts triglycerides inside HDL particles, releasing free fatty acids and shrinking the particle.
The remodeling of HDL begins with the hydrolysis of triglycerides by hepatic lipase (LIPC), which cleaves triglyceride into free fatty acids and glycerol, leading to the loss of free fatty acids from the particle. This step reduces the core lipid content of HDL and contributes to the conversion of larger HDL2 to smaller, denser HDL3 particles. Hepatic lipase activity is a key determinant of HDL subfraction distribution and is regulated by apolipoproteins and lipid environment.
CETP-Mediated Cholesteryl Ester and Triglyceride Exchange
In simple terms: CETP acts as a shuttle that swaps cholesteryl esters from HDL with triglycerides from LDL and other triglyceride-rich lipoproteins, changing the cargo of both particles.
Cholesteryl ester transfer protein (CETP) mediates the transfer of cholesteryl esters from LDL to triglyceride-rich lipoprotein particles, with the simultaneous transfer of triglyceride to LDL. This exchange is a hallmark of HDL remodeling and directly alters the lipid composition of HDL, making it more triglyceride-rich and less cholesteryl ester-rich. CETP activity is a major determinant of HDL cholesterol levels and has been a target for therapeutic inhibition to raise HDL cholesterol and reduce cardiovascular risk.
Phospholipid Transfer and Surface Remodeling
In simple terms: Phospholipid transfer protein (PLTP) moves phospholipids between lipoproteins, reshaping the HDL surface and helping particles fuse or change size.
Phospholipid transfer protein (PLTP) facilitates the transfer of phospholipids between HDL particles and other lipoproteins, contributing to the remodeling of the HDL surface and the generation of larger and smaller HDL subpopulations. This process is closely linked to the acquisition and loss of surface components, including apolipoproteins, and affects HDL stability and function. PLTP activity is also associated with inflammatory states and can be modulated by serum amyloid A (SAA) proteins that displace APOA1 on HDL.
LCAT-Mediated Esterification and Particle Maturation
In simple terms: LCAT converts free cholesterol on the HDL surface into cholesteryl esters, which move into the core and help the particle mature and change shape.
Lecithin-cholesterol acyltransferase (LCAT) esterifies free cholesterol on the surface of HDL, generating cholesteryl esters that partition into the hydrophobic core, thereby driving particle maturation and remodeling. This enzymatic activity is essential for the reverse cholesterol transport pathway and influences HDL subfraction distribution. LCAT deficiency leads to abnormal HDL remodeling and is associated with renal and cardiovascular pathology.
Postprandial and Inflammatory Remodeling
In simple terms: After a meal or during inflammation, the composition of HDL changes rapidly, altering its size and function.
Postprandial remodeling of HDL following high saturated fat or high carbohydrate meals leads to acute changes in HDL lipid composition and particle size. During inflammation, serum amyloid A (SAA) proteins can displace APOA1 and other apolipoproteins on HDL, remodeling the particle and altering its functional properties. These dynamic changes highlight the responsiveness of GO:0034375 to metabolic and inflammatory cues.
Key Genes Involved in GO:0034375 high-density lipoprotein particle remodeling
The following genes and proteins are central to high-density lipoprotein particle remodeling (GO:0034375), based on their established roles in lipid transfer, hydrolysis, and particle modification.
| Gene | Major Role | Research Relevance |
|---|---|---|
| CETP | Mediates transfer of cholesteryl esters from LDL to triglyceride-rich lipoproteins and triglyceride to LDL | Drug target for raising HDL cholesterol; genetic variants affect cardiovascular risk |
| LIPC | Hepatic lipase hydrolyzes triglycerides and phospholipids in HDL, promoting particle shrinkage | Key enzyme in HDL subfraction remodeling; linked to dyslipidemia |
| PLTP | Phospholipid transfer protein transfers phospholipids between lipoproteins, remodeling HDL surface | Modulates HDL size and function; implicated in inflammation |
| LCAT | Esterifies free cholesterol on HDL surface, driving core lipid accumulation and maturation | Essential for reverse cholesterol transport; deficiency causes renal disease |
| APOA1 | Major structural apolipoprotein of HDL; acceptor for cholesterol efflux | Target for HDL-based therapeutics; displaced by SAA during inflammation |
| APOA2 | Second most abundant HDL apolipoprotein; modulates HDL metabolism | Genetic variants influence HDL levels and cardiovascular risk |
| APOC3 | Inhibits lipoprotein lipase and hepatic lipase; affects triglyceride-rich lipoprotein metabolism | Target for triglyceride-lowering therapies |
| APOE | Mediates receptor binding and lipid transport; present on HDL subfractions | Isoform-specific effects on HDL remodeling and Alzheimer's disease risk |
| SAA1 | Acute-phase protein that displaces APOA1 on HDL during inflammation | Biomarker and mediator of inflammatory HDL remodeling |
| SAA2 | Acute-phase protein with similar remodeling effects on HDL | Contributes to HDL dysfunction in chronic inflammation |
| LPL | Lipoprotein lipase hydrolyzes triglycerides in triglyceride-rich lipoproteins, influencing HDL remodeling | Deficiency causes hypertriglyceridemia and altered HDL |
| CETP | See above; also modulates HDL particle size and subfraction distribution | Pharmacological inhibition studied for cardiovascular risk reduction |
| SCARB1 | Scavenger receptor B1 mediates selective cholesteryl ester uptake from HDL | Key receptor for HDL metabolism; affects reverse cholesterol transport |
| ABCA1 | Cholesterol efflux pump that lipidates APOA1 to form nascent HDL | Mutations cause Tangier disease with severe HDL deficiency |
| ABCG1 | Mediates cholesterol efflux to mature HDL particles | Contributes to HDL remodeling and macrophage cholesterol homeostasis |
| NR1H3 | Liver X receptor alpha regulates genes involved in cholesterol efflux and HDL remodeling | Therapeutic target for dyslipidemia and atherosclerosis |
| PPARA | Peroxisome proliferator-activated receptor alpha regulates lipid metabolism genes | Target of fibrates like pemafibrate to lower triglycerides and modify HDL |
| CETP | Cholesteryl ester transfer protein; central to HDL remodeling | Genetic and pharmacological modulation studied in cardiovascular outcomes trials |
How Is high-density lipoprotein particle remodeling Regulated?
High-density lipoprotein particle remodeling is regulated at multiple levels, including transcriptional control of key genes by nuclear receptors such as PPARA and NR1H3, which respond to lipid ligands and modulate the expression of CETP, LIPC, and apolipoproteins. Postprandial state and dietary composition acutely regulate remodeling, with high saturated fat or high carbohydrate meals altering HDL lipid composition and particle size. Inflammatory cytokines induce serum amyloid A (SAA) proteins, which displace APOA1 on HDL and remodel the particle, linking inflammation to HDL dysfunction. Additionally, enzyme activities of hepatic lipase, LCAT, and PLTP are regulated by their lipid substrates and interacting proteins, providing feedback control of the remodeling process.
high-density lipoprotein particle remodeling and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| CETP | Atherosclerotic cardiovascular disease; HDL cholesterol levels | CETP knockout or point-mutation cell models; CETP overexpression in hepatocytes |
| LIPC | Dyslipidemia; altered HDL subfractions | LIPC knockout HepG2 cells; hepatic lipase point-mutation knock-in |
| LCAT | LCAT deficiency; renal disease; abnormal HDL remodeling | LCAT knockout cell lines; LCAT knock-in with patient mutations |
| SAA1 | Inflammation; HDL dysfunction | SAA1 overexpression in hepatocytes; SAA1 knockout macrophages |
| APOA1 | Tangier disease-like HDL deficiency; cardiovascular risk | APOA1 knockout or knock-in cell models; APOA1 tagged knock-in for imaging |
Atherosclerotic Cardiovascular Disease
Dysregulated HDL remodeling is strongly associated with atherosclerotic cardiovascular disease. Altered HDL subfraction distribution and reduced cholesterol efflux capacity are observed in patients with coronary artery disease. CETP-mediated remodeling influences HDL cholesterol levels, and pharmacological inhibition of CETP has been evaluated to reduce cardiovascular risk, although clinical trials have yielded mixed results. Triglyceride lowering with pemafibrate, which indirectly affects HDL remodeling, did not significantly reduce cardiovascular events in a large trial, highlighting the complexity of targeting this process.
Renal Fibrosis and Kidney Disease
HDL nanoparticles have been shown to spontaneously target damaged renal tubules and alleviate renal fibrosis by remodeling the fibrotic niches. This suggests that HDL remodeling processes, including lipid exchange and particle modification, can be harnessed for targeted therapy in kidney disease. The study demonstrates that HDL-based nanoparticles can modulate the microenvironment and reduce fibrosis, linking GO:0034375 to renal pathology.
Inflammation and Acute-Phase Response
During acute-phase responses, serum amyloid A (SAA) proteins are upregulated and displace APOA1 on HDL, leading to remodeling of the particle and loss of its anti-inflammatory properties. This SAA-mediated remodeling is observed in chronic inflammatory conditions and contributes to HDL dysfunction, linking GO:0034375 to inflammatory diseases.
Metabolic and Osmotic Stress
Postprandial remodeling of HDL following high saturated fat or high carbohydrate meals alters particle size and composition, connecting diet to HDL function and metabolic disease risk. In goldfish under critical salinity, HDL remodeling affects the osmotic properties of plasma, indicating a role in osmotic stress adaptation. These findings expand the disease relevance of GO:0034375 beyond classical cardiovascular contexts.
From high-density lipoprotein particle remodeling-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of CETP alter HDL remodeling and cholesterol efflux? | CETP knockout cell line (e.g., HepG2) or mouse model |
| How do point mutations in LCAT affect HDL maturation? | LCAT point-mutation knock-in cell lines |
| Can tagged APOA1 track HDL particle remodeling in live cells? | APOA1 tagged knock-in (e.g., GFP or HaloTag) in hepatocytes |
| What is the effect of LIPC overexpression on HDL subfraction distribution? | LIPC overexpression in hepatic cell lines |
| Does SAA1 displace APOA1 and remodel HDL during inflammation? | SAA1 overexpression or knockout in macrophage-like cells |
| Can CRISPR library screening identify novel regulators of HDL remodeling? | Genome-wide CRISPR knockout library in a HDL remodeling reporter cell line |
How to Study the high-density lipoprotein particle remodeling Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Lipidomics (LC-MS/MS) | Lipid species composition of HDL | Quantifying cholesteryl esters and triglycerides during remodeling |
| Proteomics (LC-MS/MS) | Protein composition of HDL | Identifying apolipoproteins and surfaceome changes |
| Ultracentrifugation | HDL subfraction distribution | Monitoring HDL2 to HDL3 conversion |
| CETP activity assay | Cholesteryl ester transfer rate | Assessing CETP function in cell models |
| Hepatic lipase activity assay | Triglyceride hydrolysis rate | Evaluating LIPC function in remodeling |
| CRISPR knockout screening | Gene essentiality for HDL remodeling | Discovering novel regulators |
| Nanoparticle tracking analysis | Particle size and concentration | Real-time monitoring of HDL remodeling |
| Fluorescence microscopy | Cellular uptake and efflux of HDL | Visualizing HDL-cell interactions |
Lipidomics and Proteomics
Mass spectrometry-based lipidomics and proteomics are essential for characterizing changes in HDL lipid and protein composition during remodeling. These methods can quantify cholesteryl esters, triglycerides, phospholipids, and apolipoproteins across HDL subfractions. Surfaceome profiling has been used to decode functional HDL particle surface interactions, revealing dynamic protein networks that mediate remodeling.
Subfraction Analysis by Ultracentrifugation and Gel Filtration
Separation of HDL subfractions by density gradient ultracentrifugation or gel filtration allows researchers to monitor the conversion of HDL2 to HDL3 and other size changes during remodeling. These techniques are foundational for studying GO:0034375 and can be combined with enzymatic assays for hepatic lipase, LCAT, and CETP activity.
CRISPR Screening and Functional Genomics
Genome-wide CRISPR knockout or activation screens can identify genes that regulate HDL remodeling. By using fluorescently labeled HDL or reporters of cholesterol efflux, researchers can isolate cells with altered remodeling capacity and identify candidate regulators. This approach is particularly powerful for discovering novel genes in the CETP, LIPC, and PLTP pathways.
Imaging and Nanoparticle Tracking
Advanced imaging techniques, including super-resolution microscopy and nanoparticle tracking analysis, enable real-time visualization of HDL particle remodeling in vitro and in vivo. HDL nanoparticles can be engineered to target specific tissues, such as damaged renal tubules, and their remodeling can be tracked to assess therapeutic potential.
How CRISPR Can Be Used to Study GO:0034375 high-density lipoprotein particle remodeling
Knockout
CRISPR knockout of genes such as CETP, LIPC, LCAT, or PLTP in hepatic cell lines (e.g., HepG2, Huh7) allows researchers to determine their causal role in HDL remodeling. Knockout cells can be challenged with lipid-loaded HDL and analyzed for changes in particle size, lipid composition, and cholesterol efflux capacity. This approach is ideal for validating gene function in GO:0034375.
Point Mutation
CRISPR point mutation (base editing or homology-directed repair) can introduce disease-associated missense variants in genes like LCAT or APOA1 to study their impact on HDL remodeling. For example, LCAT mutations found in fish-eye disease can be modeled to assess enzymatic activity and particle maturation defects. Point-mutation models provide mechanistic insight into how specific amino acid changes alter remodeling.
Knock-in
Knock-in of tagged versions of APOA1, CETP, or other HDL proteins (e.g., GFP, HaloTag, or HiBiT) enables real-time tracking of particle remodeling and protein trafficking. Tagged knock-in cell lines can be used for live-cell imaging and proximity labeling to identify interacting partners during remodeling. This approach is powerful for dissecting the spatiotemporal dynamics of GO:0034375.
Overexpression
CRISPR activation (CRISPRa) or lentiviral overexpression of genes such as CETP, PLTP, or SAA1 can drive excessive HDL remodeling and mimic pathological states. Overexpression models are useful for studying the consequences of enhanced lipid transfer or inflammation-induced remodeling on HDL function and cellular cholesterol homeostasis. These models can be combined with lipidomics and proteomics to map remodeling outcomes.
How EDITGENE Supports high-density lipoprotein particle remodeling Research
Researchers studying high-density lipoprotein particle remodeling-related genes often need to determine whether a candidate gene is causally involved in the process or merely correlated with changes in HDL composition. EDITGENE provides a comprehensive suite of CRISPR-based services to enable precise genetic perturbations in relevant cell models, from knockout to point mutation, knock-in, and overexpression, as well as library screening and bioinformatics support.
Contact EDITGENE today to design your custom CRISPR model for high-density lipoprotein particle remodeling research.
Frequently Asked Questions About high-density lipoprotein particle remodeling
What is high-density lipoprotein particle remodeling?
High-density lipoprotein particle remodeling (GO:0034375) is the acquisition, loss, or modification of proteins and lipids within an HDL particle, including triglyceride hydrolysis by hepatic lipase and CETP-mediated lipid exchange.
What genes are involved in high-density lipoprotein particle remodeling?
Key genes include CETP, LIPC, PLTP, LCAT, APOA1, APOA2, APOC3, APOE, SAA1, SAA2, LPL, SCARB1, ABCA1, ABCG1, NR1H3, and PPARA.
How does CETP contribute to HDL remodeling?
CETP transfers cholesteryl esters from LDL to triglyceride-rich lipoproteins and simultaneously transfers triglyceride to LDL, altering HDL lipid composition.
What is the role of hepatic lipase in HDL remodeling?
Hepatic lipase (LIPC) hydrolyzes triglycerides in HDL, releasing free fatty acids and promoting the conversion of larger HDL2 to smaller HDL3 particles.
How does diet affect HDL remodeling?
Postprandial remodeling following high saturated fat or high carbohydrate meals changes HDL lipid composition and particle size, linking diet to HDL function.
What diseases are associated with abnormal HDL remodeling?
Atherosclerotic cardiovascular disease, dyslipidemia, renal fibrosis, and inflammatory conditions are associated with altered HDL remodeling.
Can CRISPR be used to study HDL remodeling?
Yes, CRISPR knockout, point mutation, knock-in, and overexpression models enable causal testing of genes involved in HDL remodeling.
What methods are used to study HDL remodeling?
Lipidomics, proteomics, ultracentrifugation, enzymatic assays, CRISPR screening, and imaging are commonly used.
What is the role of serum amyloid A in HDL remodeling?
SAA proteins displace APOA1 on HDL during inflammation, remodeling the particle and altering its function.
How does pemafibrate affect HDL remodeling?
Pemafibrate lowers triglycerides and may indirectly modify HDL remodeling, but its cardiovascular benefit remains under investigation.
Conclusion
GO:0034375, high-density lipoprotein particle remodeling, is a dynamic and clinically relevant biological process that governs HDL composition, size, and function. From CETP-mediated lipid exchange to hepatic lipase-driven triglyceride hydrolysis and inflammation-induced surface remodeling, this process is central to cardiovascular health and disease. Emerging evidence links HDL remodeling to renal fibrosis and osmotic stress adaptation, broadening its biological significance. For researchers, precise genetic models are essential to dissect the causal roles of individual genes in HDL remodeling. CRISPR-based knockout, point mutation, knock-in, and overexpression models, combined with lipidomics, proteomics, and screening approaches, provide a robust toolkit to advance this field. EDITGENE offers end-to-end services to accelerate discovery in HDL remodeling research.
References
- 1. He S et al.. 2025. High-density lipoprotein nanoparticles spontaneously target to damaged renal tubules and alleviate renal fibrosis by remodeling the fibrotic niches.. Nat Commun 16(1):1061 PMID: 39870661
- 2. Sack GH Jr. 2020. Serum Amyloid A (SAA) Proteins.. Subcell Biochem 94:421-436 PMID: 32189310
- 3. Zhang Y et al.. 2024. High-Density Lipoprotein Subfractions Remodeling: A Critical Process for the Treatment of Atherosclerotic Cardiovascular Diseases.. Angiology 75(5):441-453 PMID: 36788038
- 4. Frey K et al.. 2022. Decoding Functional High-Density Lipoprotein Particle Surfaceome Interactions.. Int J Mol Sci 23(16) PMID: 36012766
- 5. Andreeva AM et al.. 2024. High-density lipoprotein remodeling affects the osmotic properties of plasma in goldfish under critical salinity.. J Fish Biol 104(3):564-575 PMID: 37927095
- 6. Averill M et al.. 2020. Postprandial remodeling of high-density lipoprotein following high saturated fat and high carbohydrate meals.. J Clin Lipidol 14(1):66-76.e11 PMID: 31859127
- 7. Rye KA et al.. 2014. Regulation of high-density lipoprotein metabolism.. Circ Res 114(1):143-56 PMID: 24385508
- 8. Das Pradhan A et al.. 2022. Triglyceride Lowering with Pemafibrate to Reduce Cardiovascular Risk.. N Engl J Med 387(21):1923-1934 PMID: 36342113
